Neotrofin to enter pivotal trial in AD
NeoTherapeutics has decided to start what it believes will be a pivotaltrial of its candidate drug Neotrofin in patients with Alzheimer's disease, with a view to accelerating a New Drug Application filing for the drug. The 24-week study, due to start in April, will focus on Neotrofin's effects on the symptoms of the disease and should be completed by the end of the year, said the firm.
Thereafter, a second and larger trial will start in the second half of 2001 and look at whether Neotrofin can modify the course of AD. If both trials are positive, NeoTherapeutics will file an amendment to its original NDA to support approval of an expanded indication for the drug, which is thought to work by stimulating progenitor cells in the brain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze